Week In Review: China Group To Build $1.5 Billion Life Science Complex In South San Francisco

A China JV made up or Greenland Holdings, a China real estate developer, and three China investment funds, will invest $1.5 billion to build a life science office park in South San Francisco that fosters China-US cooperation; Huapont Life Sciences made a $6 million investment in Histogen, a San Diego stem cell company developing a treatment for hair loss; Hunan China Sun Pharma completed a $2 million investment in San Diego's Glucovation, a medical device maker; Hangzhou Cognitive Care will provide IBM's "Watson for Oncology," a best practices program, to 21 China hospitals; the CEO of Jafron Biomedical, a medical device maker, is China's newest billionaire, following the company's Shenzhen IPO; Berry Genomics of Beijing and San Diego's BioNano Genomics agreed to co-develop a next-generation mapping system to detect chromosomal structural variations; Beijing's BeiGene was approved to begin China trials of its PARP inhibitor; Ambrx, a San Diego-China biopharma, will start US clinical trials of its HER2 antibody drug conjugate; Ark Biosciences of Shanghai began dosing patients in a global Phase II trial of its treatment for RSV; and China's FDA will require drugmakers to self-report any changes to drug manufacturing procedures, followed by studies that show the changes do not harm the drug's efficacy.